- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefTM
- Patient Resources
About This Event
The International Patient & Provider Voice In Immunoglobulin A Nephropathy (IgAN)
IgAN is the most common primary glomerulonephritis in the world1 with an incidence of approximately 2.5/100,000/year.2 Clinical manifestations of IgAN range from asymptomatic microscopic hematuria to rapidly progressive glomerular nephritis.3 An estimated 20-40% of people with IgAN will progress to end stage kidney disease.4 Join us for an international panel discussion featuring members from the IgAN Foundation, expert nephrologists, patients & caregivers. Panelists will discuss living with IgAN; highlighting the similarities and differences in each patient’s journey, identify how providers can support patients, facilitate the patients’ understanding of IgAN management, and identify the current gaps in management.
1. Knoppova B, et al. Front Immunol 2016;7:117.
2. Viola P, et al. Transl Med Commun. 2016;1:7.
3. Rodrigues JC, et al. Clin J Am Soc Nephrol. 2017;12(4):677.
4. www.igan.org. Accessed January 31, 2021.
*Drs Barratt, Rizk, Liew, Jha, and Ms Schneider, Delgado, and White are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Griboldi is an employee of OPDC.
IgA Nephropathy Foundation*
Bonnie Schneider is a caregiver and director/co-founder of the IgA Nephropathy Foundation. In 2004, Bonnie’s son was diagnosed with IgAN and after finding a lack of information available and hearing that there was no ongoing research to find a cure, she quit her job in marketing and started the IgA Nephropathy Foundation with her husband, Ed.
IgA Nephropathy Foundation*
Gisela Delgado was diagnosed with IgAN at the age of 14. Ultimately, it led to her kidney failure at the age of 38 requiring a kidney transplant. Fortunately, she was able to avoid dialysis and received a pre-emptive transplant from her brother. Today she wears many hats with the IgAN Foundation, but her primary focus is developing the brand to be the trusted resource for all IgAN patients and caregivers.
“That Girl Needs a Kidney”. USA*
Malkia White has been fighting chronic kidney disease her entire life. She was diagnosed with Berger’s Disease, also known as IgAN, as a child. In November 2017, Malkia’s kidney function began to rapidly decline. On March 1, 2018, Malkia launched a Living Kidney Donor campaign entitled: #ThatGirlNeedsAKidney. This social media campaign sought not only to aid in her search for a living kidney donor, but to educate and inform all who see posts about Chronic Kidney Disease, End Stage Kidney Disease, kidney transplantation, hemodialysis, and what it’s like to be a patient fighting this disease.
University of Alabama Birmingham. Birmingham, Alabama, USA*
Dana Rizk, MD is Professor of Medicine and clinical nephrologist at the University of Alabama at Birmingham (UAB) in the division of Nephrology. She has been involved in the training and mentoring of many fellows and is the recipient of several awards for excellence in teaching. Dr Rizk is involved in clinical research and serves as site Principal Investigator on several clinical trials and NIH funded studies. She is the Director of Clinical Trials research in the division of Nephrology as well as the Medical Director of the Clinical Trials Administrative Office. Her main research interests revolve around glomerular diseases with a special focus in IgA Nephropathy.
Mount Elizabeth Novena Hospital, Singapore*
Adrian Liew, MD, MBBS, MRCP (UK), FAMS, FASN, FRCP (Edin), MClinEpid is Senior Consultant Nephrologist and Director of The Kidney and Transplant Practice at Mount Elizabeth Novena Hospital, Singapore, and is a member of several KDIGO Guideline working groups. Dr Liew is responsible for the implementation of renal initiatives in Singapore and in the development of glomerular disease and peritoneal dialysis programs in Southeast Asia. He chairs the Asian-Pacific Society of Nephrology Guideline working group on diabetic kidney disease and is a member and/or chairs several ISN committees/groups. He is also the national leader and global steering committee member for various multicenter clinical trials. His research interests include glomerular diseases, peritoneal dialysis and diabetic kidney disease.
George Institute for Global Health. New Delhi, India*
Vivekanand Jha, MD, DM, FRCP (London), FRCP (Edin), FAMS is the Executive Director at The George Institute for Global Health, India, Chair of Global Kidney Health, Faculty of Medicine, Imperial College of London, and the President of the International Society of Nephrology. Professor Jha has wide-ranging research interests, including understanding the health and societal impact of kidney diseases around the world and development of affordable, scalable and sustainable primary and secondary prevention tools. He has worked with many organizations including the WHO to develop clinical practice guidelines and advocacy papers, has lectured extensively around the world, and is a prolific writer and editor.
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Josh Gariboldi, PharmD, BCPS is a Nephrology Clinical & Scientific Liaison with Otsuka. Dr Gariboldi earned his Doctor of Pharmacy degree from the University of Florida in 2012. He has more than eight years of experience as a clinical pharmacist in both the community and hospital settings, most recently at Bon Secours Mercy Health St. Francis Hospital in Greenville, SC.
University of Leicester. Leicester, UK*
Jonathan Barratt, MBChB (Hons), PhD, FRCP is a professor and researcher, IgAN Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases, an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology, and sits on the Kidney Research UK Grants Committee. His research is focused on the pathogenesis of IgAN and a range of areas across renal medicine. He also participates in other IgAN initiatives and has been Principal Investigator for international randomized controlled clinical trials in IgAN.
Audio/Podcast December 14, 2022
In this podcast, Dr Edgar Lerma will present an overview of IgA nephropathy and a stepwise approach to identify and diagnose patients.
Downloadable Resource July 15, 2022
This downloadable resource provides an overview of the PKD Foundation’s Centers of Excellence Program.
Downloadable Resource August 11, 2020
This presentation will discuss the pathophysiology, disease progression, and the physical & emotional burden of autosomal dominant polycystic kidney disease (ADPKD). The key factors that play into ADPKD disease diagnosis…
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.May 2020 MRC2.CORP.X.04767
January 31 from 12:00 pm to 1:00 pm
February 14 from 12:00 pm to 1:00 pm
- Resource Center
- Patient Resources